First Turn Management »

Nuvalent Inc-a shares owned by First Turn Management

Quarter-by-quarter ownership of Nuvalent Inc-a (NUVL) shares owned by First Turn Management from 13F filings

Historical chart of First Turn Management investment in Nuvalent Inc-a

Tip: Access up to 7 years of quarterly data

All positions including Nuvalent Inc-a held by First Turn Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Nuvalent Inc-a by First Turn Management

Quarter filed Position value Share count Share price at filing
2023-12-31 $19M 256k 73.59

More positions owned by First Turn Management

Cytokinetics Com New (CYTK)
Cymabay Therapeutics
Vertex Pharmaceuticals Incorporated (VRTX)
Argenx Se Sponsored Adr (ARGX)
Xenon Pharmaceuticals (XENE)
Krystal Biotech (KRYS)
Legend Biotech Corp Sponsored Ads (LEGN)
Karuna Therapeutics Ord
Transmedics Group (TMDX)
Insulet Corporation (PODD)
Day One Biopharmaceuticals I (DAWN)
Mirum Pharmaceuticals (MIRM)
Verona Pharma Sponsored Ads (VRNA)
Dex (DXCM)
Axsome Therapeutics (AXSM)

View all positions for First Turn Management

Top funds holding Nuvalent Inc-a

Deerfield Management Company
Paradigm Biocapital Advisors
Vanguard Group
Perceptive Advisors
Fairmount Funds Management
Commodore Capital
Boxer Capital
T. Rowe Price Associates
Wellington Management Company
D. E. Shaw & Co
Lord, Abbett & Co
Ikarian Capital
Soleus Capital Management
Fred Alger Management
Dimensional Fund Advisors

View all funds holding Nuvalent Inc-a